Releases - MOBERG DERMA AB

View:

2010

 

Found press releases

 

MOBERG DERMA WITHDRAWS ITS IPO

12/13/2010 2:00 AM EST
The board of directors of Moberg Derma AB (publ.) has decided to withdraw the proposed listing on NASDAQ OMX Stockholm, as the demand from investors was not sufficient to ensure a successful post IPO life on the stock exchange.
“We have experienced great interest from investors in Moberg Derma as a company. However, we and our advisors have underestimated the climate for initial public offerings and listings...

PUBLICATION OF SUPPLEMENT TO PROSPECTUS REGARDING OFFER TO SUBSCRIBE FOR SHARES ...

12/3/2010 11:02 AM EST
Today Moberg Derma AB (publ.) (”Moberg Derma”) has published a supplement to the previously published prospectus regarding offer to subscribe for shares in Moberg Derma. The supplementary prospectus has been prepared following the press release on 3 December 2010 in which Moberg Derma announces that Moberg Derma has signed an agreement for distribution in Switzerland.

MOBERG DERMA SIGNS DISTRIBUTION AGREEMENT IN SWITZERLAND

12/3/2010 10:00 AM EST
Moberg Derma AB (publ.) has entered into a distribution agreement with Gebro Pharma AG S.A. for Emtrix® – for treatment of discolored and deformed nails resulting from fungal infection  (onychomycosis) or psoriasis, and Kaprolac® – for problems with dry and flaky skin and. Under the agreement, Gebro is granted exclusive rights to market and sell Emtrix®, Kaprolac® Dandruff Shampoo and Kaprolac® Scalp Solution in...

PUBLICATION OF SUPPLEMENT TO PROSPECTUS REGARDING OFFER TO SUBSCRIBE FOR SHARES ...

11/18/2010 6:10 AM EST
Today Moberg Derma AB (publ) (”Moberg Derma”) has published a supplement to the previously published prospectus regarding offer to subscribe for shares in Moberg Derma. The supplementary prospectus has been prepared due to that Moberg Derma on November 16, 2010 has been granted the permit to initiate a clinical phase II-trial for MOB-015 from the Swedish Medical Products Agency.

MOBERG DERMA IS GRANTED PERMIT TO INITIATE PHASE II-TRIAL FOR MOB-015

11/17/2010 2:00 AM EST
The Swedish Medical Products Agency has granted Moberg Derma permit to initiate a clinical phase II trial for MOB-015. MOB-015 is Moberg Dermas next generation topical treatment for nail fungus, with fungicidal, keratolytic and emollient properties.
Nail fungus (onychomycosis) chiefly manifests itself in thickening and discoloration of the nails. The disease is common, affecting about 100 million patients in...

MOBERG DERMA TO LIST ON NASDAQ OMX STOCKHOLM

11/15/2010 2:30 AM EST
The Board of Directors of Moberg Derma AB (publ) has applied for a listing of its shares on NASDAQ OMX Stockholm, the main list. In connection with the listing, Moberg Derma will broaden the ownership through a new issue of SEK 140m.

· The offer comprises a new issue of SEK 140 million corresponding to 3,111,112 – 3,783,784 shares as well as an over-allotment option of up to SEK 21 million through a new...

MOBERG DERMA SIGNS AGREEMENT FOR EMTRIX® IN PORTUGAL AND 10 MARKETS IN AFRICA AN...

11/11/2010 3:30 AM EST
Moberg Derma AB today announced that a distribution agreement has been entered into with Laboratorio EDOL Produtos Farmaceuticos S.A. for Emtrix® – Moberg Derma’s product for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement EDOL is granted exclusive rights to market and sell Emtrix® in Portugal and ten markets in Africa and Central America. Moberg Derma will...

Antula launches Nalox™ in the Nordic region– Pharmacies report major demand for ...

9/14/2010 3:00 AM EST
Moberg Derma’s market partner in the Nordic countries – Antula Healthcare, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals – has now launched sales of Nalox™ in the Nordic region. Pharmacies have displayed great interest in Moberg Derma’s product Nalox™ – a treatment for discoloured and damaged nails caused by nail fungus or nail psoriasis.

MOBERG DERMA ACQUIRES CREDIT FACILITY OF 50 MSEK

8/16/2010 4:26 AM EST
Moberg Derma has acquired a credit facility totaling SEK 50 million. The agreement runs for two years. The facility will be used to finance day-to-day operations. The facility may be drawn on as required from 1 January 2011.

The lender is Shejk Mohammed H. Al Amoudi  who is also a shareholder in Moberg Derma, with a 2.5% holding. Västra Hamnen Fondkondkommission AB has acted as consultant to Shejk Mohammed H. Al...

MOBERG DERMA SIGNS DISTRIBUTION AGREEMENT WITH PERRIGO

8/13/2010 9:00 AM EST
Moberg Derma AB, Sweden, today announced a commercial agreement with Perrigo Company that covers distribution in Israel for Moberg Derma’s novel topical nail product Emtrix™ – a treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Moberg Derma assumes supply responsibility, while the distributor will be responsible for registration and promotion in...

MOBERG DERMA AB


  CONTACT